Citations

Showing 10 of 108094 citations.

Tumors of the Central Nervous System
Burger, Peter C. , Scheithauer, Bernd W.

Mayo Clinic

No container title available | July 1, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.55418/9781933477015 Get It

SETDB1 acts as a topological accessory to Cohesin via an H3K9me3-independent, genomic shunt for regulating cell fates
Warrier, Tushar , Farran, Chadi A. El , Zeng, Yingying , Ho, Benedict Shao Quan, Bao, Qiuye , Zheng, Zihao , Bi, Xuezhi , Ong, Derrick Sek Tong , Sanyal, Amartya , Fullwood, Melissa J. , El Farran, Chadi A , Ng, Huck‐Hui , Chu, Justin Jang Hann , Collins, James J , Li, Hu , Xu, Jian , Loh, Yuin‐Han

Mayo Clinic

Nucleic Acids Research | July 1, 2022 | Volume: 50 | Issue: 13 | Pages: 7326-7349

10.1093/nar/gkac531 | PMID 35776115 Get It

Abstract SETDB1 is a key regulator of lineage-specific genes and endogenous retroviral elements (ERVs) through its deposition of repressive H3K9me3 mark. Apart from its H3K9me3 regulatory role, SETDB1 has seldom been studied in terms of its other potential regulatory roles. To investigate this, a genomic survey of SETDB1 binding in mouse embryonic stem cells across multiple libraries was conducted, leading to the unexpected discovery of regions bereft of common repressive histone marks (H3K9me3, H3K27me3). These regions were enriched with the CTCF motif that is often associated with the topological regulator Cohesin. Further profiling of these non-H3K9me3 regions led to the discovery of a cluster of non-repeat loci that were co-bound by SETDB1 and Cohesin. These regions, which we named DiSCs (domains involving SETDB1 and Cohesin) were seen to be proximal to the gene promoters involved in embryonic stem cell pluripotency and lineage development. Importantly, it was found that SETDB1-Cohesin co-regulate target gene expression and genome topology at these DiSCs. Depletion of SETDB1 led to localized dysregulation of Cohesin binding thereby locally disrupting topological structures. Dysregulated gene expression trends revealed the importance of this cluster in ES cell maintenance as well as at gene ‘islands’ that drive differentiation to other lineages. The ‘unearthing’ of the DiSCs thus unravels a unique topological and transcriptional axis of control regulated chiefly by SETDB1.
Exercise Counters the Age-Related Accumulation of Senescent Cells
Zhang, Xu , Englund, Davis A. , Aversa, Zaira, Jachim, Sarah K. , White, Thomas A. , Zhang, Xu , LeBrasseur, Nathan K. , Englund, Davis A.

Mayo Clinic

Exercise and Sport Sciences Reviews | July 1, 2022 | Volume: 50 | Issue: 4 | Pages: 213-221

10.1249/jes.0000000000000302 | PMID 35776782 Get It

We propose the beneficial effects of exercise are in part mediated through the prevention and elimination of senescent cells. Exercise counters multiple forms of age-related molecular damage that initiate the senescence program and activates immune cells responsible for senescent cell clearance. Preclinical and clinical evidence for exercise as a senescence-targeting therapy and areas needing further investigation are discussed.
Distinctions in PCOS Induced by Letrozole Vs Dehydroepiandrosterone With High-fat Diet in Mouse Model
Poojary, Pooja Suresh , Nayak, Guruprasad, Panchanan, Gangotri, Rao, A. Chandrasekhara , Kundapur, Sanjna Das, Kalthur, Sneha Guruprasad , Mutalik, Srinivas , Zhao, Yulian , Chang, Alice Y. , DeStephano, Christopher C. , Kalthur, Guruprasad , Bakkum-Gamez, Jamie, DeStephano, Christopher, Sherman, Mark , Kannan, Nagarajan , Kalthur, Guruprasad , Adiga, Satish Kumar , Bakkum‐Gamez, Jamie N. , Sherman, Mark E. , Kannan, Nagarajan

Mayo Clinic

Endocrinology | July 1, 2022 | Volume: 163 | Issue: 9 | Pages: No page available

10.1210/endocr/bqac097 | PMID 35776497 Get It

Abstract Polycystic ovarian syndrome (PCOS) is a complex health condition associated with metabolic disturbances and infertility. Recent data suggest that the prevalence of PCOS is increasing among women globally, although the etiology of these trends is undefined. Consequently, preclinical models that better reflect the biology of PCOS are urgently needed to facilitate research that can lead to the discovery of prevention strategies or improved management. The existing animal models have several limitations as they do not reflect all the PCOS features metabolically and/or phenotypically. Therefore, there is no clear consensus on the use of appropriate animal model and selection of the most appropriate PCOS-inducing agent. To that end, we have established a Swiss albino mouse model of PCOS based on 3 weeks of daily treatment with letrozole (50 μg/day; intraperitoneal) and dehydroepiandrosterone (DHEA, 6 mg/100 g body weight; subcutaneous) in 5-week-old female mice fed on normal or high-fat diet (HFD). Mice were regularly assessed for body weight, blood glucose, and estrous cycle. Three weeks after drug administration, mice were sacrificed and assessed for blood-based metabolic parameters as well as ovarian function. Our results indicate that DHEA combined with HFD produces changes mimicking those of clinical PCOS, including elevated serum testosterone and luteinizing hormone, dyslipidemia, poor ovarian microenvironment, and development of multiple ovarian cysts, recapitulating cardinal features of PCOS. In comparison, normal diet and/or letrozole produced fewer features of PCOS. The data from the experimental models presented here can improve our understanding of PCOS, a growing concern in women’s health.
Psychosis as a Treatment Target in Dementia: A Roadmap for Designing Interventions
Agüera-Ortíz, Luis , Bruneau, Marie‐Andrée , Creese, Byron , D’Antonio, Fabrizia , Ismail, Zahinoor , Mortby, Moyra E. , Núñez, Nicolás A. , Oliveira, Fabricio Ferreira de , Pereiro, Arturo X. , Ravona‐Springer, Ramit , Rouse, Hillary J , Wang, Huali , Babulal, Ganesh M. , Fischer, Corinne Eleanor , Gatchel, Jennifer R. , Kumar, Sanjeev , McGeown, William J. , Lanctôt, Krista L.

Mayo Clinic

Journal of Alzheimer’s Disease | July 1, 2022 | Volume: 88 | Issue: 4 | Pages: 1203-1228

10.3233/jad-215483 | PMID 35786651 Get It

Psychotic phenomena are among the most severe and disruptive symptoms of dementias and appear in 30% to 50% of patients. They are associated with a worse evolution and great suffering to patients and caregivers. Their current treatments obtain limited results and are not free of adverse effects, which are sometimes serious. It is therefore crucial to develop new treatments that can improve this situation. We review available data that could enlighten the future design of clinical trials with psychosis in dementia as main target. Along with an explanation of its prevalence in the common diseases that cause dementia, we present proposals aimed at improving the definition of symptoms and what should be included and excluded in clinical trials. A review of the available information regarding the neurobiological basis of symptoms, in terms of pathology, neuroimaging, and genomics, is provided as a guide towards new therapeutic targets. The correct evaluation of symptoms is transcendental in any therapeutic trial and these aspects are extensively addressed. Finally, a critical overview of existing pharmacological and non-pharmacological treatments is made, revealing the unmet needs, in terms of efficacy and safety. Our work emphasizes the need for better definition and measurement of psychotic symptoms in dementias in order to highlight their differences with symptoms that appear in non-dementing diseases such as schizophrenia. Advances in neurobiology should illuminate the development of new, more effective and safer molecules for which this review can serve as a roadmap in the design of future clinical trials.
Association of Histologic Parameters with Outcome in C3 Glomerulopathy and Idiopathic Immunoglobulin-Associated Membranoproliferative Glomerulonephritis
Lomax-Browne, Hannah J. , Medjeral‐Thomas, Nicholas , Barbour, Sean J. , Gisby, Jack , Han, Heedeok , Fervenza, Fernando C. , Cairns, Thomas H D, Szydlo, Richard , Marks, Stephen D. , Waters, Aoife , Appel, Gerald B., D’Agati, Vivette D. , Sethi, Sanjeev , Nast, Cynthia C. , Bajema, Ingeborg M., Licht, Christoph , Cattran, Daniel C., Peters, James E. , Cook, H. Terence , Marks, Stephen D , Sethi, Sanjeev , Pickering, Matthew C , Fervenza, Fernando C , Bomback, Andrew S. , Tan, Sven‐Jean , Alpers, Charles E. , Fogo, Agnes B. , Fakhouri, Fádi

Mayo Clinic

Clinical Journal of the American Society of Nephrology | July 1, 2022 | Volume: 17 | Issue: 7 | Pages: 994-1007

10.2215/cjn.16801221 | PMID 35777834 Get It

Background and objectives C3 glomerulopathy and idiopathic Ig-associated membranoproliferative GN are kidney diseases characterized by abnormal glomerular complement C3 deposition. These conditions are heterogeneous in outcome, but approximately 50% of patients develop kidney failure within 10 years. Design, setting, participants, & measurements To improve identification of patients with poor prognosis, we performed a detailed analysis of percutaneous kidney biopsies in a large cohort of patients. Using a validated histologic scoring system, we analyzed 156 native diagnostic kidney biopsies from a retrospective cohort of 123 patients with C3 glomerulopathy and 33 patients with Ig-associated membranoproliferative GN. We used linear regression, survival analysis, and Cox proportional hazards models to assess the relationship between histologic and clinical parameters with outcome. Results Frequent biopsy features were mesangial expansion and hypercellularity, glomerular basement membrane double contours, and endocapillary hypercellularity. Multivariable analysis showed negative associations between eGFR and crescents, interstitial inflammation, and interstitial fibrosis/tubular atrophy. Proteinuria positively associated with endocapillary hypercellularity and glomerular basement membrane double contours. Analysis of second native biopsies did not demonstrate associations between immunosuppression treatment and improvement in histology. Using a composite outcome, risk of progression to kidney failure associated with eGFR and proteinuria at the time of biopsy, cellular/fibrocellular crescents, segmental sclerosis, and interstitial fibrosis/tubular atrophy scores. Conclusions Our detailed assessment of kidney biopsy data indicated that cellular/fibrocellular crescents and interstitial fibrosis/tubular atrophy scores were significant determinants of deterioration in kidney function.
Is There a Bias Toward Unvaccinated COVID-19 Patients?
Jama, Abbas B., Mushtaq, Hisham, Jain, Nitesh , Khan, Syed Anjum , Khedr, Anwar , Jain, Nitesh K, Koritala, Thoyaja , Jama, Abbas B

Mayo Clinic

HCA Healthcare Journal of Medicine | July 1, 2022 | Volume: 3 | Issue: 3 | Pages: No page available

10.36518/2689-0216.1392 | PMID 37424619 Get It

With more than 22% of the United States still not vaccinated for COVID-19, we are trying to shed some light on whether there is any bias when treating unvaccinated COVID-19 patients. We highlight several reports where some individuals or organizations displayed possible bias, whether implicit or explicit. We examine the legal and ethical implications of these biases and offer a general overview of how to tackle them.
Conscious and Unconscious Bias: The Hidden Pandemic of Biases in Healthcare Exacerbated by COVID-19
Rauf, Ibtisam , Hartmann, Abigail, Koumtchev, Alexandre, Khan, Syed Anjum , Kashyap, Rahul

Mayo Clinic

HCA Healthcare Journal of Medicine | July 1, 2022 | Volume: 3 | Issue: 3 | Pages: No page available

10.36518/2689-0216.1376 | PMID 37424618 Get It

Background There are limited data on unconscious bias in healthcare, but there is consistent evidence that it alters clinical decision-making. COVID-19 exacerbated many pre-existing disparities, and this paper seeks to identify, deconstruct, and propose mitigation strategies for a few of them. Discussion Five of the largest disparities amplified by the pandemic are discussed in this paper. Older people, Black people, uninsured people, rural communities, and people with lower education levels have been disproportionally affected in both morbidity and mortality. Conclusions The disparities discussed above did not occur in a vacuum but are the result of systemic issues. Equity starts with understanding and addressing the root cause, and it can be worked toward with practical and impactful solutions.
Body weight changes and associated predictors in a prospective cohort of young breast cancer survivors
Sella, Tal , Tan‐Wasielewski, Zhenying, Rosenberg, Shoshana M. , Poorvu, Philip D. , Tayob, Nabihah , Ruddy, Kathryn J. , Gelber, Shari , Schapira, Lidia , Come, Steven E. , Peppercorn, Jeffrey , Ligibel, Jennifer A. , Rosenberg, Shoshana , Ruddy, Kathryn J , Schapira, Lidia , Partridge, Ann H , Zheng, Yue , Tamimi, Rulla M. , Borges, Virginia F. , Partridge, Ann H.

Mayo Clinic

Cancer | July 1, 2022 | Volume: 128 | Issue: 17 | Pages: 3158-3169

10.1002/cncr.34342 | PMID 35775874 Get It

BackgroundWeight gain after a breast cancer diagnosis is common and is associated with inferior outcomes. Young survivors may be especially susceptible to weight changes given the impact of treatment on menopausal status.MethodsThe authors identified women who were diagnosed with stage 0 to III breast cancer at age 40 years or younger between 2006 and 2016 from a multicenter prospective cohort. Self‐reported weight was collected at diagnosis and at 1 year and 3 years postdiagnosis. Tumor and treatment data were obtained from medical records and patient surveys. Multinomial logistic regression was used to identify the factors associated with weight gain (≥5%) or weight loss (≥5%) versus stable weight at 1 year and 3 years postdiagnosis.ResultsThe cohort included 956 women with a median age of 37 years at diagnosis. Mean weight significantly increased over time from 66.54 ± 14.85 kg at baseline to 67.33 ± 15.53 and 67.77 ± 14.65 kg at 1 year and 3 years, respectively (p ≤ .001 for both comparisons). The proportion of women experiencing ≥5% weight gain increased from 24.8% at 1 year to 33.9% at 3 years. At 1 year, less self‐perceived financial comfort, Black race, and stage III disease were significantly associated with weight gain; at 3 years, only less self‐perceived financial comfort remained significant. Baseline overweight or obesity was significantly associated with weight loss at both time points. Chemotherapy, endocrine therapy, and treatment‐related menopause were not associated with weight change.ConclusionsOne third of young breast cancer survivors experienced clinically significant weight gain 3 years after diagnosis; however, treatment‐related associations were not observed. Age‐appropriate lifestyle interventions, including the reduction of financial barriers, are needed to prevent weight gain in this high‐risk population.
Perioperative risk stratification of spine trauma patients with ankylosing spinal disorders: a comparison of 3 quantitative indices
Lakomkin, Nikita , Mikula, Anthony L. , Wellings, Elizabeth P. , Scheitler, Kristen M. , Pennington, Zach , Lee, Nathan J. , Freedman, Brett A. , Sebastian, Arjun S. , Fogelson, Jeremy L. , Bydon, Mohamad , Elder, Benjamin D. , Wellings, Elizabeth, Pennington, Zach , Pinter, Zachariah W. , Alvi, Mohammed Ali , Clarke, Michelle J.

Mayo Clinic

Journal of Neurosurgery: Spine | July 1, 2022 | Volume: 37 | Issue: 5 | Pages: 722-728

10.3171/2022.4.spine211449 | PMID 35623371 Get It

OBJECTIVE Patients with ankylosing spinal disorders (ASDs), including ankylosing spondylitis (AS) and diffuse idiopathic skeletal hyperostosis (DISH), have been shown to experience significantly increased rates of postoperative complications. Despite this, very few risk stratification tools have been validated for this population. As such, the purpose of this study was to identify predictors of adverse events and mortality in ASD patients undergoing surgery for 3-column fractures. METHODS All adult patients with a documented history of AS or DISH who underwent surgery for a traumatic 3-column fracture between 2000 and 2020 were identified. Perioperative variables, including comorbidities, time to diagnosis, and number of fused segments, were collected. Three instruments, including the Charlson Comorbidity Index (CCI), modified frailty index (mFI), and Injury Severity Score (ISS), were computed for each patient. The primary outcomes of interest included 1-year mortality, as well as postoperative complications. RESULTS A total of 108 patients were included, with a mean ± SD age of 73 ± 11 years. Of these, 41 (38%) experienced at least 1 postoperative complication and 22 (20.4%) died within 12 months after surgery. When the authors controlled for potential known confounders, the CCI score was significantly associated with postoperative adverse events (OR 1.20, 95% CI 1.00–1.42, p = 0.045) and trended toward significance for mortality (OR 1.19, 95% CI 0.97–1.45, p = 0.098). In contrast, mFI score and ISS were not significantly predictive of either outcome. CONCLUSIONS Complications in spine trauma patients with ASD may be driven by comorbidity burden rather than operative or injury-related factors. The CCI may be a valuable tool for the evaluation of this unique population.